AU2003301059A1 - Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof - Google Patents
Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereofInfo
- Publication number
- AU2003301059A1 AU2003301059A1 AU2003301059A AU2003301059A AU2003301059A1 AU 2003301059 A1 AU2003301059 A1 AU 2003301059A1 AU 2003301059 A AU2003301059 A AU 2003301059A AU 2003301059 A AU2003301059 A AU 2003301059A AU 2003301059 A1 AU2003301059 A1 AU 2003301059A1
- Authority
- AU
- Australia
- Prior art keywords
- screening
- compositions
- treating
- methods
- inflammatory bowel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5431—IL-11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43435602P | 2002-12-18 | 2002-12-18 | |
| US43436202P | 2002-12-18 | 2002-12-18 | |
| US43433802P | 2002-12-18 | 2002-12-18 | |
| US60/434,338 | 2002-12-18 | ||
| US60/434,362 | 2002-12-18 | ||
| US60/434,356 | 2002-12-18 | ||
| PCT/US2003/040383 WO2004058307A1 (en) | 2002-12-18 | 2003-12-18 | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003301059A1 true AU2003301059A1 (en) | 2004-07-22 |
Family
ID=32686072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003301059A Abandoned AU2003301059A1 (en) | 2002-12-18 | 2003-12-18 | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20040176293A1 (en) |
| AU (1) | AU2003301059A1 (en) |
| WO (1) | WO2004058307A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888789A2 (en) * | 2005-06-06 | 2008-02-20 | Wyeth a Corporation of the State of Delaware | Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases |
| US20090258848A1 (en) * | 2005-12-06 | 2009-10-15 | The Johns Hopkins University | Biomarkers for inflammatory bowel disease |
| US20070224638A1 (en) * | 2006-03-27 | 2007-09-27 | Institut Pasteur | Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections |
| DE102006040444A1 (en) * | 2006-08-29 | 2008-03-13 | Forschungszentrum Jülich GmbH | Sample preparation procedure for the quantitative analysis of samples containing amino acids |
| HUE038588T2 (en) * | 2007-11-07 | 2018-10-29 | Genentech Inc | For use in the treatment of IL-22 microbial disorders |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EA035645B1 (en) | 2013-03-15 | 2020-07-21 | Дженентек, Инк. | IL-22 POLYPEPTIDES, IL-22 Fc FUSION PROTEINS AND USE THEREOF |
| PT2968443T (en) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Hepcidin analogues and uses therof |
| SG10201810321PA (en) | 2014-05-16 | 2018-12-28 | Protagonist Therapeutics Inc | α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS |
| ES2977537T3 (en) | 2014-07-17 | 2024-08-26 | Protagonist Therapeutics Inc | Oral peptide inhibitors of the interleukin-23 receptor and their use in treating inflammatory bowel diseases |
| SG11201702553RA (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics Inc | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| EP4092038A1 (en) | 2017-09-11 | 2022-11-23 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP3997105A4 (en) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES |
| IL294680A (en) | 2020-01-15 | 2022-09-01 | Janssen Biotech Inc | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CN115279782A (en) | 2020-01-15 | 2022-11-01 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| IL302996B2 (en) | 2020-11-20 | 2025-04-01 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| AU2022311814A1 (en) | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6126933A (en) * | 1995-06-27 | 2000-10-03 | Genetics Institute | Methods of treating inflammatory bowel diseases by administering IL-11 |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| EP1341817A2 (en) * | 2000-12-08 | 2003-09-10 | Novo Nordisk A/S | Tff peptides |
-
2003
- 2003-12-18 AU AU2003301059A patent/AU2003301059A1/en not_active Abandoned
- 2003-12-18 US US10/740,218 patent/US20040176293A1/en not_active Abandoned
- 2003-12-18 WO PCT/US2003/040383 patent/WO2004058307A1/en not_active Ceased
-
2008
- 2008-01-22 US US12/017,857 patent/US20080206261A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20040176293A1 (en) | 2004-09-09 |
| WO2004058307A1 (en) | 2004-07-15 |
| US20080206261A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003301059A1 (en) | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof | |
| EP1545578A4 (en) | Compositions and methods for treating cardiovascular disease | |
| AU2003295511A8 (en) | Methods and compositions for diagnosing dysplasia | |
| EP1667730A4 (en) | Compositions and methods for treating inflammatory lung disease | |
| AU2003300368A1 (en) | Methods and compositions for the diagnosis, prognosis, and treatment of cancer | |
| AU2003298703A1 (en) | Diagnostic tests and methods for diagnosing inflammatory bowel disease | |
| AU2003268032A1 (en) | Composition and methods for treatment and screening | |
| EP1496893A4 (en) | Neuroprotectant methods, compositions, and screening methods thereof | |
| AU2003212850A1 (en) | Methods and compositions for treating cardiovascular disease | |
| AU2003215376A1 (en) | Methods for diagnosing akathisia | |
| EP1583966A4 (en) | Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32 | |
| AU2003290948A1 (en) | Screening methods to identify treatments for autoimmune disease | |
| EP1576109A3 (en) | Methods and compositions for categorizing patients | |
| AU2003301348A1 (en) | Compositions and methods for diagnosing and treating autoimmune disease | |
| EP1572085A3 (en) | Methods and compositions for treating and diagnosing diabetes | |
| EP1572085A4 (en) | Methods and compositions for treating and diagnosing diabetes | |
| AU2003277202A1 (en) | Methods for diagnosing bone turnover disease | |
| AU2003273243A1 (en) | Method for treating inflammatory bowel disease | |
| EP1511506A4 (en) | Compositions and methods for preventing, treating and diagnosing diabetes | |
| AU2002322515A1 (en) | Compositions, methods, and kits related to treating and diagnosing hypertension | |
| AU2003284166A1 (en) | Methods for diagnosing and treating pre-term labor | |
| AU2003294206A1 (en) | Methods for diagnosing htlv-i-mediated diseases | |
| AU2003285503A1 (en) | Screening method | |
| AU2003243450A1 (en) | Test for lyme disease | |
| EP1667677A4 (en) | Composition for treating inflammatory bowel disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |